ESTRO meets Asia 2024 - Abstract Book

S167

Interdisciplinary – Head & neck

ESTRO meets Asia 2024

Five databases (PubMed, Embase, Cochrane, ProQuest, and Scopus) were searched based on the search strategy and selection criteria. Primary endpoints were objective response rate (ORR) and progression-free survival (PFS). The secondary endpoints were disease control rate (DCR), overall survival (OS), metastatic sites, and adverse events (AE). Pooled estimates were calculated using a random-effects meta-analysis. As most studies did not report detail data about PFS and OS, the survival data was extracted from Kaplan-Meier(K-M) curves using software Engauge Digitizer version 11.3, then survival curve is pooled by ‘MetaSurv’ packages in RStudio (R version 4.3.0)[1][2].

Results:

Finally, 28 studies, involving 849 patients, were included. The most common metastatic sites were the lungs, bones, liver, lymph nodes, and kidneys. The pooled ORR of targeted therapy was 4.0% (95% CI,0.7%-8.8%), the pooled DCR of targeted therapy was 80.5% (95% CI, 72.2%-87.7%). Compared with other targeted drugs, multiple kinase inhibitors (MKIs) improved exhibited higher the ORR (pooled ORR for other targeted drugs vs. MKIs: 0% vs. 5.9%). However, there was no significant change in disease control rates (DCR) between other targeted drugs and MKIs. The combination of MKIs and immune checkpoint inhibitors (ICIs) had a significantly higher ORR (17.9% in the axitinib + velumab group). The combination of EGFR and chemotherapy had a significantly higher ORR, the pooled median PFS and OS of targeted therapy were 8.35 months and 25.62 months, respectively. MKIs improved the median PFS compared to other targeted drugs (9.43 months vs 5.06 months). In addition, the most common adverse events (AEs) were fatigue (all grade: 51.6%, ≥grade III: 14.0%), hypertension (all grade: 44.2%, ≥grade III: 17.9%), and nausea (all grade: 40.0%, ≥grade III: 3.2%), followed by hand-foot skin syndrome (all grade: 36.8%, ≥grade III: 5.5%), vomiting(all grade: 35.2%, ≥grade III: 4.8%) , diarrhea (all grade: 34.4%, ≥grade III: 3.9%), weight